Gemphire to Host Key Opinion Leader Lunch on the Evolving NASH Landscape

LIVONIA, Mich., May 04, 2017 (GLOBE NEWSWIRE) — Gemphire Therapeutics Inc. (GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic disorders, including dyslipidemia and NASH, will host a key opinion leader (KOL) lunch to discuss the evolving nonalcoholic steatohepatitis (NASH) landscape in New York City on Tuesday, May 9 from 12:00pm – 1:30pm Eastern Time.